In the ever-evolving landscape of healthcare, there are numerous initiatives and strategic directions being implemented to address the broken incentives that govern the system. From the passage of the One Big Beautiful Bill to CMS’s newly announced strategic direction, it is evident that a fundamental shift is needed to align incentives, promote transparency, and hold stakeholders accountable for the value they provide.
Currently, each segment of the healthcare ecosystem operates within its own silo, prioritizing revenue generation over outcomes and sustainability. This fragmented approach has resulted in a system that rewards inefficiency and punishes reform. Hospitals invest in costly outpatient facilities, insurers profit from denying claims, PBMs chase rebates that inflate drug costs, and pharmaceutical manufacturers face barriers to promoting cheaper generic drugs. Even programs like 340B have strayed from their original purpose of serving vulnerable populations.
To truly address the systemic issues in healthcare, a new business model is essential—one that focuses on delivering value, promoting transparency, and fostering competition. The existing model, which prioritizes volume over outcomes, must be reevaluated and redesigned to ensure better health outcomes at lower costs.
CMS’s new strategy emphasizes accountability and site-neutral payments, signaling a move towards rationalizing care delivery. However, true change must extend beyond policy guidance to actual implementation by provider organizations. Investing in models that prioritize results over compliance is crucial, particularly in underserved areas where a distributed, tech-enabled system is needed.
Payers also need to undergo a reset, transitioning from gatekeepers to health partners. By adopting a value-based model that aligns financial incentives with long-term health outcomes, insurers can enhance trust and relevance. Utilization management should focus on evidence-based, cost-effective care rather than blanket barriers that hinder patient access.
The dysfunction in drug pricing, particularly with PBMs, calls for a shift towards value-based principles. Eliminating rebate-driven incentives, mandating transparency, and tying formulary placement to outcomes are essential steps in reforming the pharmaceutical supply chain.
Medicare, Medicaid, and programs like 340B play a crucial role in supporting vulnerable populations, but they must also be subject to scrutiny to ensure efficient use of public healthcare funds. CMS’s new strategic direction holds promise in linking payment models to cost and outcomes, but ongoing accountability is key to driving meaningful change.
In conclusion, the current healthcare model is unsustainable and in need of a fundamental shift towards outcomes, transparency, and competition. By embracing a new business model grounded in value, stakeholders can work towards better results for patients, taxpayers, and companies. The path forward may be challenging, but it is imperative for the future of healthcare.
